Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
